Immunotech Biopharm Ltd
HHKEX:69780.37
HKD
-0.01
(-3.90%)
ISIN
KYG4721A1004
CUSIP
G4721A100
Return %
Stock
S&P 500
1Y
-89.15
14.20
3Y
-89.91
81.12
5Y
-97.56
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jian Zhang
- Full Time Employees
- 183
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Guosheng Technology Park Beijing BE China
- IPO Date
- Jul 10, 2020
- Website
- eaal.net
- Similar Companies
- Business
- Immunotech Biopharm Ltd (6978.HK) is a China-based investment holding company engaged in the research, development, manufacturing and commercialization of cellular immunotherapy products for cancer treatments, primarily operating in the People's Republic of China; its core offerings include the multi-target cellular immunotherapy product EAL for solid tumors such as liver cancer, lung cancer, glioma, gastric cancer and colorectal cancer, which has entered Phase II clinical trials and received breakthrough therapy designation from China's CDE in September 2023; non-genetically modified products like 6B11-OCIK Injection for ovarian cancer; chimeric antigen receptor T-cell (CAR-T) series including CAR-T-19 Injection for B-cell acute lymphoblastic leukemia, RC19D2 (Denocabtagene Ciloleucel) for non-Hodgkin lymphoma, aT19 for acute lymphoblastic leukemia and others targeting multiple myeloma, T-cell lymphoma and solid tumors; T-cell receptor engineered T-cell (TCR-T) series such as YT003, YT008, YT007, TCR-T-CMV and TCR-T-EBV for solid tumors, blood tumors and post-transplant infections; as well as cell cryopreservation services. Founded in 2006 and headquartered at 8th Floor, Block 1, Guosheng Technology Park, No.1 Kangding Street, Beijing Economic and Technological Development Zone, Beijing, China, the company maintains a pipeline of over 10 gene and cell therapy products covering gene-modified and non-gene-modified, multi-target and single-target categories, supported by nearly 80 core technology patents, GMP-compliant digital manufacturing facilities spanning nearly 30,000 square meters in Beijing with advanced systems like SCADA, LIMS and MES, and a workforce of approximately 154 employees. Recent developments encompass the advancement of five immune cell therapy products into clinical trials as of June 2024, including EAL's Phase II solid tumor studies and gene-modified products like aT19, RC19D2 and CAR-T-19; ongoing construction and utilization of its Beijing R&D and industrialization base initiated in June 2021 for pre-clinical and clinical support; allocation of placement proceeds announced in August 2024 toward EAL clinical trials with expected full utilization by mid-2025; strategic plans for endogenous growth through collaborations, potential acquisitions, technology transfers and expansion into new cellular immunotherapy directions; and a historical corporate minority investment, underscoring its focus on scaling production standardization and addressing industry challenges in China's CGT sector.